Back to Journals » Vascular Health and Risk Management » Volume 10

Validation of the custo screen 400 ambulatory blood pressure-monitoring device according to the European Society of Hypertension International Protocol revision 2010

Authors Bramlage P, Deutsch C, Krüger R, Wolf A, Müller P, Zwingers T, Beime B, Mengden T

Received 5 March 2014

Accepted for publication 4 April 2014

Published 13 May 2014 Volume 2014:10 Pages 303—309


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Peter Bramlage,1 Cornelia Deutsch,1 Ralf Krüger,1 Andreas Wolf,2 Peter Müller,2 Thomas Zwingers,1,4 Beate Beime,1 Thomas Mengden3

1Institut für Pharmakologie und Präventive Medizin, Cloppenburg, 2Müller and Sebastiani, Ottobrunn, 3Kerckhoff-Klinik, Bad Nauheim, 4Estimate, Augsburg, Germany

Objective: The aim of the present study was to validate the custo screen 400 ambulatory blood pressure-monitoring (ABPM) device according to the 2010 International Protocol revision of the European Society of Hypertension (ESH-IP). The device can be used for ABPM for up to 72 hours.
Materials and methods: Systolic and diastolic blood pressure (SBP and DBP, respectively) were sequentially measured in 33 adult subjects (13 males and 20 females) and compared with a standard mercury sphygmomanometer (two observers). A total of 99 comparison pairs were obtained.
Results: The custo screen 400 met the requirements of parts 1 and 2 of the ESH-IP revision 2010. The mean difference between the device and reference sphygmomanometer readings was −0.5±4.5 mmHg for SBP and −0.1±3.3 mmHg for DBP. All but one measurement were within the absolute difference of 10 mmHg between the device and the observers for SBP and DBP. The number of absolute differences between the device and the observers within a range of 5 mmHg was 84 of 99 readings for SBP, and 93 of 99 readings for DBP.
Conclusion: The custo screen 400 ABPM device met the requirements of the 2010 ESH-IP revision, and hence can be recommended for ABPM in adults. To our knowledge, the custo screen 400 is the first device to pass the revised ESH-IP 2010.

Keywords: validation, ambulatory blood pressure monitoring, ESH

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice

Bramlage P, Fronk EM, Wolf WP, Smolnik R, Sutton G, Schmieder RE

Vascular Health and Risk Management 2015, 11:1-8

Published Date: 17 December 2014

Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice

Bramlage P, Zemmrich C, Ketelhut R, Wolf WP, Fronk EM, Schmieder RE

Vascular Health and Risk Management 2013, 9:475-483

Published Date: 26 August 2013

Diabetes prevalence and metabolic risk profile in an unselected population visiting pharmacies in Switzerland

Rey A, Thoenes M, Fimmers R, Meier CA, Bramlage P

Vascular Health and Risk Management 2012, 8:541-547

Published Date: 21 September 2012

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery

Turpie AG, Schmidt AC, Kreutz R, Lassen MR, Jamal W, Mantovani L, Haas S

Vascular Health and Risk Management 2012, 8:363-370

Published Date: 1 June 2012

Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study

Schmieder RE, Goebel M, Bramlage P

Vascular Health and Risk Management 2012, 8:177-186

Published Date: 15 March 2012

Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice

Peter Bramlage, Wolf-Peter Wolf, Thomas Stuhr, et al

Vascular Health and Risk Management 2010, 6:803-811

Published Date: 27 August 2010

Readers of this article also read:

Monitoring cancer stem cells: insights into clinical oncology

Lin SC, Xu YC, Gan ZH, Han K, Hu HY, Yao Y, Huang MZ, Min DL

OncoTargets and Therapy 2016, 9:731-740

Published Date: 11 February 2016

miR-195 is a key regulator of Raf1 in thyroid cancer

Wang F, Jiang C, Sun Q, Yan F, Wang L, Fu Z, Liu T, Hu F

OncoTargets and Therapy 2015, 8:3021-3028

Published Date: 20 October 2015

BRAF mutation as a biomarker in colorectal cancer

Varghese AM, Saltz LB

Advances in Genomics and Genetics 2015, 5:347-353

Published Date: 15 October 2015

Skull base metastasis from papillary thyroid carcinoma: a report of three cases

Tunio MA, Al Asiri M, Al-Qahtani KH, Aldandan S, Riaz K, Bayoumi Y

International Medical Case Reports Journal 2015, 8:127-131

Published Date: 25 June 2015

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology

Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M

OncoTargets and Therapy 2015, 8:1149-1156

Published Date: 22 May 2015

Effect of blood type on survival of Chinese patients with esophageal squamous cell carcinoma

Qin J, Wu SG, Sun JY, Lin HX, He ZY, Li Q

OncoTargets and Therapy 2015, 8:947-953

Published Date: 23 April 2015

Brachytherapy in the treatment of cervical cancer: a review

Banerjee R, Kamrava M

International Journal of Women's Health 2014, 6:555-564

Published Date: 28 May 2014

A triple negative breast cancer: what it is not!

Katakkar SB

Breast Cancer: Targets and Therapy 2012, 4:21-23

Published Date: 24 February 2012

Multidisciplinary care in pediatric oncology

Cantrell MA, Ruble K

Journal of Multidisciplinary Healthcare 2011, 4:171-181

Published Date: 30 May 2011